Literature DB >> 8869766

Autoradiographic distribution of [3H]sumatriptan-binding sites in post-mortem human brain.

J Pascual1, C del Arco, T Romón, E del Olmo, E Castro, A Pazos.   

Abstract

The anatomical distribution of [3H]sumatriptan-binding sites was analysed in brain tissue sections from 11 subjects. Relevant concentrations of [3H]sumatriptan-binding sites were seen in areas such as visual cortex > locus niger > globus pallidus > layers IV-V of the frontal cortex > subiculum > entorhinal cortex > nucleus tractus solitarius > nucleus trigeminalis caudalis. This distribution of [3H]sumatriptan-binding sites in the human brain shows some differences when compared with that of 5HT1D receptors, confirming that, besides 5HT1D, sumatriptan also binds to 5HT1F receptor subtype. Some species differences are evident between the distribution of [3H]sumatriptan-binding sites in the human brain and that reported for guinea-pig and rat brains, emphasizing that caution is needed in extrapolating experimental data from animals to humans. Furthermore, these data help to explain some of the therapeutic actions of sumatriptan. The remarkable levels of binding found in areas as nucleus tractus solitarius and nucleus trigeminalis caudalis suggest that in migraine attacks sumatriptan could exert its specific anti-emetic effects and, partly at least, induce analgesia by directly acting over these brain nuclei.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8869766     DOI: 10.1046/j.1468-2982.1996.1605317.x

Source DB:  PubMed          Journal:  Cephalalgia        ISSN: 0333-1024            Impact factor:   6.292


  9 in total

1.  [3H]LY334370, a novel radioligand for the 5-HT1F receptor. II. Autoradiographic localization in rat, guinea pig, monkey and human brain.

Authors:  Virginia L Lucaites; Joseph H Krushinski; John M Schaus; James E Audia; David L Nelson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2005-04-27       Impact factor: 3.000

Review 2.  Where does a migraine attack originate? In the brainstem.

Authors:  J Tajti; D Szok; Á Párdutz; B Tuka; A Csáti; A Kuris; J Toldi; L Vécsei
Journal:  J Neural Transm (Vienna)       Date:  2012-03-18       Impact factor: 3.575

Review 3.  5-HT(1F) Receptor agonists: a new treatment option for migraine attacks?

Authors:  Lars Neeb; Jannis Meents; Uwe Reuter
Journal:  Neurotherapeutics       Date:  2010-04       Impact factor: 7.620

Review 4.  Preclinical neuropharmacology of naratriptan.

Authors:  Geoffrey A Lambert
Journal:  CNS Drug Rev       Date:  2005

Review 5.  Central sensitisation and cutaneous allodynia in migraine: implications for treatment.

Authors:  Stephen Landy; Kathryn Rice; Bob Lobo
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

Review 6.  Does sumatriptan cross the blood-brain barrier in animals and man?

Authors:  Peer Carsten Tfelt-Hansen
Journal:  J Headache Pain       Date:  2009-12-10       Impact factor: 7.277

Review 7.  Sumatriptan. An updated review of its use in migraine.

Authors:  C M Perry; A Markham
Journal:  Drugs       Date:  1998-06       Impact factor: 9.546

8.  Autoradiographic Mapping of 5-HT(1B/1D) Binding Sites in the Rhesus Monkey Brain Using [carbonyl-C]zolmitriptan.

Authors:  Orjan Lindhe; Per Almqvist; Matts Kågedal; Sven-Åke Gustafsson; Mats Bergström; Dag Nilsson; Gunnar Antoni
Journal:  Int J Mol Imaging       Date:  2011-10-12

9.  The Use of Neuroimaging for Predicting Sumatriptan Treatment Response in Patients With Migraine.

Authors:  Jr-Wei Wu; Pi-Yi Lai; Yung-Lin Chen; Yen-Feng Wang; Jiing-Feng Lirng; Shu-Ting Chen; Kuan-Lin Lai; Wei-Ta Chen; Yu-Te Wu; Shuu-Jiun Wang
Journal:  Front Neurol       Date:  2022-01-31       Impact factor: 4.003

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.